These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 14565788)

  • 21. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer.
    Park K; Goto K
    Curr Med Res Opin; 2006 Mar; 22(3):561-73. PubMed ID: 16574039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials.
    Ku GY; Haaland BA; de Lima Lopes G
    Lung Cancer; 2011 Dec; 74(3):469-73. PubMed ID: 21565418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer.
    Manegold C; Gatzemeier U; Buchholz E; Smith RP; Fandi A
    Clin Lung Cancer; 2005 May; 6(6):343-9. PubMed ID: 15943894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
    Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
    Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
    Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib.
    Reck M; Gatzemeier U
    Lung Cancer; 2005 Oct; 50(1):107-14. PubMed ID: 15985306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
    Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
    Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolerability of gefitinib in patients receiving treatment in everyday clinical practice.
    van Zandwijk N
    Br J Cancer; 2003 Dec; 89 Suppl 2(Suppl 2):S9-14. PubMed ID: 14661047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gefitinib in advanced non-small cell lung cancer.
    Sharma R; Boyer M; Clarke S; Millward M
    Intern Med J; 2005 Feb; 35(2):77-82. PubMed ID: 15705135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gefitinib: a second look. Non-small cell lung cancer: still very disappointing.
    Prescrire Int; 2009 Aug; 18(102):145-7. PubMed ID: 19739343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.
    Niho S; Kubota K; Goto K; Yoh K; Ohmatsu H; Kakinuma R; Saijo N; Nishiwaki Y
    J Clin Oncol; 2006 Jan; 24(1):64-9. PubMed ID: 16382114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).
    Gaafar RM; Surmont VF; Scagliotti GV; Van Klaveren RJ; Papamichael D; Welch JJ; Hasan B; Torri V; van Meerbeeck JP;
    Eur J Cancer; 2011 Oct; 47(15):2331-40. PubMed ID: 21802939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.
    Morita S; Okamoto I; Kobayashi K; Yamazaki K; Asahina H; Inoue A; Hagiwara K; Sunaga N; Yanagitani N; Hida T; Yoshida K; Hirashima T; Yasumoto K; Sugio K; Mitsudomi T; Fukuoka M; Nukiwa T
    Clin Cancer Res; 2009 Jul; 15(13):4493-8. PubMed ID: 19531624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
    Yamaguchi H; Soda H; Nakamura Y; Takasu M; Tomonaga N; Nakano H; Doi S; Nakatomi K; Nagashima S; Takatani H; Fukuda M; Hayashi T; Tsukamoto K; Kohno S
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):331-8. PubMed ID: 20401612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gefitinib: new preparation. Non small-cell lung cancer: stricter assessment needed.
    Prescrire Int; 2004 Oct; 13(73):168-70. PubMed ID: 15499696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
    Argiris A; Mittal N
    Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
    Shao YY; Lin CC; Yang CH
    Discov Med; 2010 Jun; 9(49):538-45. PubMed ID: 20587343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gefitinib therapy for non-small cell lung cancer.
    Birnbaum A; Ready N
    Curr Treat Options Oncol; 2005 Jan; 6(1):75-81. PubMed ID: 15610717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.